Anixa Biosciences announced encouraging survival results from its ongoing Phase 1 clinical trial of lira-cel, a CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The trial enrolls women who have progressed after at least two prior treatments. Lira-cel uses a novel approach where the natural ligand FSH binds to the tumor receptor, differentiating it from other therapies. The company will present detailed trial data at the ISCT 2026 Annual Meeting in May, highlighting its potential to improve outcomes in difficult-to-treat ovarian cancer cases.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Gold and silver prices are under pressure ahead of key U.S. retail sales data that could influence Federal Reserve interest rate decisions. Central banks, led by Poland and China, continue to boost gold reserves, adding 41 tonnes in May, supporting l...
